Great Britain Moves Toward First-Ever CBD Novel Food Authorizations, Covering About 3,000 Products
- Great Britain’s Food Standards Agency (FSA) has recommended approval of three high-purity CBD novel foods, marking the first potential authorizations of CBD products as novel foods in the country.
- The applications cover synthetic CBD from Chanelle McCoy CBD Ltd., CBD isolate from Cannaray Brands Ltd., and hemp-derived CBD isolate from EIHA projects GmbH, all with at least 98% purity and positive safety assessments for adults consuming up to 10 mg per day.
- The FSA’s recommendations follow a public consultation with 68% support and aim to bring approximately 3,000 CBD products currently on the market into regulatory compliance, requiring labeling of intake limits and warnings for vulnerable groups.
- If approved by ministers, these authorizations would apply primarily to food supplements, with Cannaray’s isolate also approved for certain beverages and confectionery, and signal a major step forward in regulating the UK CBD food sector.
Great Britain is moving toward its first-ever authorizations of CBD products as novel foods, with regulators recommending approval of three applications linked to approximately 3,000 individual products currently on the market.
The Food Standards Agency (FSA) published recommendations September 3 calling for the authorization of three high-purity CBD novel foods. The agency’s board is scheduled to consider the recommendations at its September 16 meeting before advice is submitted to ministers in England and Wales, who will make the final authorization decisions.
The three applications cover synthetic CBD from Chanelle McCoy CBD Ltd., CBD isolate from Cannaray Brands Ltd., and hemp-derived CBD isolate from EIHA projects GmbH.
All three contain CBD at a purity of at least 98% and have received positive safety assessments. The FSA said they were found safe under their proposed conditions of use for adults consuming no more than 10 milligrams of CBD per day.
If ministers approve the applications, the authorizations would be the first of their kind in Great Britain.
There are approximately 3,000 individual CBD products on the FSA’s existing Public List that are linked to the three applications. The list was established as an interim system allowing regulators to distinguish products connected to applications progressing through the novel-food approval process.
Products on the list are not currently formally authorized as novel foods.
The FSA said authorization would represent “a major milestone in the regulation of the CBD food sector” and a significant step toward bringing the existing CBD market into regulatory compliance.
Under the proposed conditions, products would be required to display information reflecting the FSA’s provisional acceptable daily intake of 10 milligrams of CBD. Labels would also include warnings for people under 18, those who are pregnant, breastfeeding or trying to conceive, people taking medication and those who are immunosuppressed.
The products would also be subject to specifications limiting delta-9 THC and other controlled cannabinoids.
All three CBD ingredients are being recommended for authorization in food supplements. The Cannaray application would additionally allow its CBD isolate to be used in certain beverages and confectionery products.
The recommendations follow a 12-week public consultation that received 46 responses from consumers, businesses, trade associations, local authorities and others. The FSA said 68% of respondents supported its overall proposed approach.
The agency said it has now published positive safety assessments for 14 applications involving CBD products with purity levels above 97%, meaning additional authorization recommendations could follow.
Final approval of the first three applications remains in the hands of government ministers. The FSA board is being asked September 16 to agree that the recommendations are suitable for submission to ministers.